Lost Money on Gritstone bio, Inc.(GRTS)? Join Class Action Suit Seeking Recovery

Core Viewpoint - The article discusses a class action lawsuit against Gritstone bio, Inc. (NASDAQ: GRTS) due to allegations of misleading statements regarding the company's COVID-19 vaccine development and its financial implications for investors [2][4]. Allegations - The complaint alleges that Gritstone made materially false and misleading statements, failing to disclose that it would be unable to launch the Phase 2b CORAL Study for its COVID-19 vaccine as previously represented [2]. - This inability to launch the study is said to impair Gritstone's ability to secure external funding, negatively affecting its balance sheet and cash position [2]. - Consequently, Gritstone is accused of overstating its capability to develop and commercialize its products, leading to materially false public statements throughout the relevant period [2]. Class Action Details - The class period for the lawsuit is defined as March 9, 2023, to February 29, 2024, with a deadline for shareholders to seek lead plaintiff status set for August 6, 2024 [6]. - Shareholders who purchased GRTS shares during this period are encouraged to register for the class action, with no cost or obligation to participate [3][6]. - The Gross Law Firm, which is handling the case, emphasizes its commitment to protecting investors' rights against deceit and fraud [6].